Sandra A. Springer

Biography

Sandra A. Springer, M.D. is an Assistant Professor of Medicine within the Department of Medicine, Section of Infectious Diseases at Yale School of Medicine. Her primary clinical interest is HIV/AIDS and caring for HIV infected patients at the Veterans Administrative Hospital as Director of the Newington Infectious Disease clinic as well as within the Connecticut State Prisons. Her research interests include improving adherence to antiretrovirals and drug treatment for HIV infected opiate and alcohol dependent men and women. Clinical research includes treating opiate addiction and HIV infection with directly observed buprenorphine in conjunction with antiretroviral therapy as well as using naltrexone as relapse prevention for HIV-infected alcohol dependent prisoners prior to release and continued after release to improve adherence to antiretroviral therapy as well as decrease risk of relapse to alcohol use. She has received a 5 year K23 Career Development Award from NIDA to study adherence interventions for HIV-infected opiate dependent released prisoners providing directly observed antiretroviral therapy and buprenorphine treatment. She has also recently been awarded a 5 year grant from NIAAA as co-P.I. with Frederick Altice, M.D. to evaluate alcohol pharmacotherapies for HIV-infected prisoners. Sandra A. Springer, M.D. is an Assistant Professor of Medicine within the Department of Medicine, Section of Infectious Diseases at Yale School of Medicine. Her primary clinical interest is HIV/AIDS and caring for HIV infected patients at the Veterans Administrative Hospital as Director of the Newington Infectious Disease clinic as well as within the Connecticut State Prisons. Her research interests include improving adherence to antiretrovirals and drug treatment for HIV infected opiate and alcohol dependent men and women. Clinical research includes treating opiate addiction and HIV infection with directly observed buprenorphine in conjunction with antiretroviral therapy as well as using naltrexone as relapse prevention for HIV-infected alcohol dependent prisoners prior to release and continued after release to improve adherence to antiretroviral therapy as well as decrease risk of relapse to alcohol use. She has received a 5 year K23 Career Development Award from NIDA to study adherence interventions for HIV-infected opiate dependent released prisoners providing directly observed antiretroviral therapy and buprenorphine treatment. She has also recently been awarded a 5 year grant from NIAAA as co-P.I. with Frederick Altice, M.D. to evaluate alcohol pharmacotherapies for HIV-infected prisoners.

Research Interest

Improving adherence to antiretrovirals and drug treatment for HIV infected opiate and alcohol dependent men and women. Treating opiate addiction and HIV infection with directly observed buprenorphine in conjunction with antiretroviral therapy